查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2098968

DNA定序市場－2026-2032年全球市場預測

DNA Sequencing Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，DNA定序市場將成長至 652.8 億美元，複合年成長率為 17.09%。

主要市場統計數據
基準年 2025 216.2億美元
預計年份：2026年 252.2億美元
預測年份 2032 652.8億美元
複合年成長率 (%) 17.09%

DNA定序簡介

DNA定序已成為精準醫療、罕見疾病診斷、腫瘤學、生殖醫學、感染疾病監測、農業和人群基因組學等領域的基礎技術。隨著次世代定序、長讀長定定序、單細胞定序和元基因組定序等技術的出現，分析深度和工作流程柔軟性不斷提升，DNA定序產業正從以研究為中心的應用轉向常規臨床、公共衛生和工業應用。這項需求主要源自於基因生物標記日益成長的臨床意義、伴隨診斷的普及以及對快速病原體檢測和抗生素抗藥性監測的需求。同時，DNA定序的應用也需要檢驗的檢查室工作流程、生物資訊能力、資料管治、明確的保險報銷機制以及人才培養。經營團隊重點也從單純產生定序資料轉向將基因組資訊轉化為臨床可解釋、安全且可操作的洞見。

DNA定序領域的變革性變化

DNA定序領域正經歷變革，這得益於樣品製備速度的提升、高通量定序儀的出現、讀取準確性的提高以及長讀長和多組體學技術的廣泛應用。儘管短讀長定定序在許多臨床和研究工作流程中仍然佔據核心地位，並得到成熟方案和廣泛的生物資訊學支持，但長讀長定定序在結構變異、重複序列擴增、單倍型分析以及難以用短讀長定序解析的複雜基因組區域等方面正變得日益重要。臨床檢查室越來越重視自動化、從樣本到結果的工作流程、品管以及與電子健康記錄的互通性。公共衛生機構也正在藉鏡全球病原體監測的經驗，將基因組監測納入其應對感染疾病爆發的措施中。該行業最顯著的轉變是從一次性定序項目向整合樣本處理、變異解釋、數據安全和決策支持的連續基因組智慧系統的過渡。

人工智慧對DNA定序的累積影響

人工智慧透過改進鹼基鑑定、序列比對、突變優先排序、註釋、品管和臨床解讀，正在加速DNA定序的發展。機器學習模型在檢測複雜突變模式、過濾定定序偽影、對未知意義的突變進行分類以及整合基因組學發現與觀察和臨床數據方面尤為有效。人工智慧驅動的生物資訊學減輕了人工審核的負擔，並支持在腫瘤基因組、全EXOME定序、全基因測序、藥物基因體學組學、總體基因體學和單細胞資料集等多個領域進行可擴展的分析。然而，人工智慧的累積效應取決於透明的模型檢驗、偏差評估、可解釋性、安全的資料存取以及對醫療設備、檢查室和隱私相關法規的遵守。行業領導者正擴大採用「人機協同」系統，其中人工智慧輔助進行分診和解讀，而合格的專業人員則繼續負責臨床報告和病患安全。

DNA定序的關鍵區域見解

北美在臨床基因組學、腫瘤檢測、罕見疾病定序、新生兒篩檢研究和人群健康舉措方面仍然保持著高度領先地位，這得益於成熟的檢查室網路、強力的法律規範以及先進的生物資訊能力。在歐洲，人工智慧的應用正透過合作基因組學策略、以隱私為中心的數據框架、跨境研究計畫以及定序日益融入國家醫療保健體係而取得顯著進展。亞太地區正成為DNA定序應用的主要成長引擎，這主要得益於基因組醫學計畫的擴展、臨床研究活動的活性化、感染疾病監測的加強以及中國、日本、印度、韓國、澳洲和東南亞國協對生物技術基礎設施投資的增加。在拉丁美洲，大學醫院、公共衛生實驗室和區域參考網路正在推動相關領域的發展，其中巴西和墨西哥在感染疾病基因組學和遺傳疾病研究方面發揮著重要作用，儘管資金和准入方面仍然存在挑戰。非洲的定序生態系統正透過病原體基因組學、抗菌素抗藥性監測、生物多樣性研究和能力建設項目得到加強，這需要持續關注本地檢查室基礎設施、數據主權和熟練的生物資訊人才。在中東，國家基因組舉措、精準醫療投資和醫院基因組服務正在取得進展，尤其是在醫療現代化和國家衛生計畫是政策優先事項的地區。

領先的團隊對DNA定序的見解

北約成員國透過強大的基因組監測系統為DNA定序做出貢獻，這些系統支援生物安全、感染疾病監測、國防相關健康調查以及應對生物威脅的準備。七國集團（G7）仍然是DNA定序創新、監管科學、臨床應用和先進舉措的核心，在腫瘤學、藥物基因體學、罕見疾病診斷和病原體監測方面發揮重要作用。歐盟正在建構一個系統化的臨床定序擴展環境，其特點是協調一致的基因組計劃、強力的倫理和隱私管治，以及專注於在醫學和研究領域使用可互通的基因組數據。金磚國家由於其龐大的人口基數、多樣化的疾病種類、不斷成長的生物技術能力以及公共衛生領域日益活躍的定序活動，對DNA測序產生了重大影響，但在測序服務的可及性、標準化和人力資源開發方面存在相當大的差異。東南亞國協正在透過感染疾病監測、腫瘤學研究、農業基因組學以及學術和臨床夥伴關係加強其DNA定序能力，但成員國之間的定序應用模式仍受到檢測基礎設施和報銷政策差異的影響。海灣合作理事會國家在現代醫院系統的支持下，以及對數據驅動型醫療保健日益成長的興趣，正透過國家衛生改革議程、人口基因組學、罕見疾病診斷和精準腫瘤學來優先發展基因組醫學。

主要國家DNA定序的發展趨勢

憑藉先進的檢測設施、法律規範和廣泛的生物醫學研究網路，美國在腫瘤學、罕見疾病、生殖醫學、藥物基因組學和公共衛生基因組學等領域的臨床DNA定序應用方面處於主導。中國在人群基因組學、生殖醫學、腫瘤學、農業和感染疾病監測方面擁有強大的定序能力，並日益重視國內創新和數據管治。德國憑藉其強大的臨床檢查室、轉化研究和工業生物技術能力，正大力推進基因組診斷；英國則將定序融入醫療保健路徑、癌症診斷、罕見疾病計畫和人群基因組學，打造了全球最完善的國家基因組學體系之一。加拿大強調精準醫療、罕見疾病研究、癌症基因組學和公共衛生定序，並致力於確保各省和偏遠社區的公平獲取。日本則將先進的臨床研究、癌症基因組學、老齡化相關研究和高標準的檢查室技術結合。同時，印度正透過大規模人口調查、罕見疾病計畫、病原體定序、農業以及經濟高效的診斷方法，迅速加強其基因組學生態系統。法國致力於在全國推廣基因組醫學、腫瘤學、罕見疾病診斷和資料管治。墨西哥正透過感染疾病監測、遺傳性癌症研究以及學術界與醫療機構的合作來擴大定序，而巴西則透過病原體監測、生物多樣性相關定序和臨床研究，在拉丁美洲基因組學領域發揮關鍵作用。韓國正憑藉其先進的醫院系統和國家生物技術優先事項，推動精準醫療、腫瘤定序、罕見疾病診斷和數位健康整合。義大利和西班牙正在擴大腫瘤學、遺傳疾病、生殖醫學和大學醫院網路的臨床定序。澳洲正透過其國家基因組醫學計劃、公共衛生基因組學、原住民健康考量以及強大的研究基礎設施來支持定序。俄羅斯在生物醫學研究、感染疾病監測和農業領域進行定序活動，但能否融入常規臨床護理取決於基礎設施和政策狀況。

為DNA定序的領導者提供的實用建議

產業領導者應優先考慮經臨床檢驗的定序流程、擴充性的生物資訊學以及支援與實驗室資訊系統和電子健康記錄互通性的安全資料架構。拓展臨床DNA定序領域的機構應投資於品管認證、標準化變異分類、能力測試以及多學科基因組解讀團隊。為促進應用，領導者需要將定序服務與明確的應用情境結合，例如腫瘤治療方案選擇、罕見疾病診斷、感染疾病監測、藥物基因體學和生殖醫學。人工智慧應在經過檢驗和人工監督的情況下選擇性地應用於品管、變異優先排序和報告等高價值功能。與醫院、公共衛生組織、學術機構和保險公司夥伴關係可以提高證據產生、臨床效用評估和保險報銷準備的效率。經營團隊也應加強網路安全、知情同意管理、資料在地化合規性和長期基因組資料管理，以維護人們對定序驅動醫學的信​​心。

調查方法

本執行摘要採用系統性的二手研究資訊來源檢驗，基於已核實的公開資源，包括同行評審的科學文獻、臨床實踐指南、監管出版刊物、公共衛生基因組學資源、國家基因組學計畫文件、標準化機構以及衛生政策參考資料。分析重點在於定序技術、臨床應用、生物資訊學、人工智慧、區域滲透率和管治要求等方面的實證研究途徑。資訊評估標準包括相關性、時效性、資訊來源可靠性以及獨立參考文獻之間的一致性。調查方法避免了對市場規模的推測性估算、市場佔有率分析和預測，而是著重於可觀察的行業趨勢、已驗證的應用、政策方向以及對DNA定序相關相關人員的營運影響。

結論

DNA定序正從一項專業研究能力發展成為精準醫療、公共衛生和生物創新領域的核心基礎設施。其最具潛力的領域包括臨床應用基因組學、人工智慧驅動的解讀、長讀長定序、病原體監測、人群健康計劃以及基因組數據與醫療保健系統的安全整合。在那些實驗室能夠證明其分析有效性、臨床效用、合規性、資料保護和永續報銷途徑的領域，DNA定序的應用最為廣泛。在區域和國家層面，DNA定序不再局限於特定地區，而是正在成為全球性能力，其發展受到醫療保健優先事項、公共衛生準備和生物技術投資的影響。那些能夠將穩健的定序工作流程與可靠的解讀、合乎倫理的資料管治和明確的臨床價值結合的機構，將最有能力引領下一階段的基因組變革。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 DNA定序市場：依服務類型分類

  • 耗材和試劑
    • 酵素和緩衝液
    • 引子和探針
    • 定序盒
  • 設備和平台
    • DNA定序儀
    • 樣品製備系統
    • PCR裝置
  • 服務
    • 合約定序
    • 生物資訊學和數據分析服務
  • 軟體
    • 基地識別軟體
    • 臨床解讀平台
    • 結構變異的檢測

第8章：DNA定序市場：依技術類型分類

  • 次世代定序（NGS）
    • 合成定序
    • 奈米孔定序
    • 離子半導體定序
  • 桑格定序
  • 第三代定序（TGS）
  • 表觀遺傳定序
    • 亞硫酸氫鹽定序
    • ChIP定序

第9章：DNA定序市場：依樣本類型分類

  • 人類檢體
    • 血
    • 唾液和口腔黏膜拭子
    • 尿
    • 無細胞DNA
    • 組織
    • 電漿
  • 動物性樣本
  • 植物樣品
    • 葉子
    • 根
    • 種子
  • 微生物樣本
    • 細菌
    • 病毒
    • 真菌
    • 古菌

第10章：DNA定序市場：依應用領域分類

  • 臨床診斷
    • 腫瘤學
    • 感染疾病診斷
    • 罕見疾病和遺傳疾病的檢測
    • 生殖醫學和產前檢查
    • 新生兒篩檢
  • 出於研究目的
    • 基因組學和轉錄組學
    • 功能基因體學
    • 表觀遺傳學研究
  • 藥物發現與開發
    • 生物標記的發現
    • 伴隨診斷
    • 目標識別與檢驗
  • 農業基因組學
    • 植物育種和性狀發現
    • 作物病原體監測
  • 法醫學與安全
    • 個人識別
    • 刑事調查
    • 識別災難受害者

第11章 DNA定序市場：依最終用戶分類

  • 學術和研究機構
    • 政府附屬研究機構
    • 大學研究實驗室
  • 受託研究機構
  • 醫院/診斷檢查室
  • 製藥和生物技術公司

第12章 DNA定序市場：按地區分類

  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 非洲
  • 中東

第13章：DNA定序市場：依組別分類

  • NATO
  • G7
  • EU
  • BRICS
  • ASEAN
  • GCC

第14章 DNA定序市場：依國家分類

  • 美國
  • 中國
  • 德國
  • 英國
  • 加拿大
  • 日本
  • 印度
  • 法國
  • 墨西哥
  • 巴西
  • 韓國
  • 義大利
  • 澳洲
  • 俄羅斯
  • 西班牙

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • BGI Genomics Co., Ltd.
  • Oxford Nanopore Technologies PLC
  • Pacific Biosciences of California, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novogene Co, Ltd.
  • Laboratory Corporation of America Holdings
  • Eurofins Scientific SE
  • QIAGEN NV
  • Azenta, Inc.
  • Agilent Technologies, Inc.
  • Twist Bioscience Corporation
  • 10x Genomics, Inc.
  • Abbott Laboratories
  • AbbVie Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioChain Institute Inc.
  • Charles River Laboratories International, Inc.
  • Danaher Corporation
  • Eppendorf SE
  • GeneDx, LLC
  • Genomics England
  • Genscript Biotech Corporation
  • Johnson & Johnson Services, Inc.
  • Macrogen Inc.
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Novartis AG
  • Partek Inc.
  • PerkinElmer, Inc.
  • Sartorius AG
  • Shimadzu Corporation
Product Code: MRR-450A0628CCF5

The DNA Sequencing Market is projected to grow by USD 65.28 billion at a CAGR of 17.09% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 21.62 billion
Estimated Year [2026] USD 25.22 billion
Forecast Year [2032] USD 65.28 billion
CAGR (%) 17.09%

DNA Sequencing Introduction

DNA sequencing has become a foundational technology for precision medicine, rare disease diagnosis, oncology, reproductive health, infectious disease surveillance, agriculture, and population-scale genomics. The industry is advancing from research-centered applications toward routine clinical, public health, and industrial use as next-generation sequencing, long-read sequencing, single-cell sequencing, and metagenomic sequencing improve analytical depth and workflow flexibility. Demand is supported by the growing clinical relevance of genomic biomarkers, broader use of companion diagnostics, and the need for faster pathogen detection and antimicrobial resistance monitoring. At the same time, DNA sequencing adoption depends on validated laboratory workflows, bioinformatics capacity, data governance, reimbursement clarity, and workforce readiness. Executive priorities are shifting from simply generating sequence data to converting genomic information into clinically interpretable, secure, and actionable insights.

Transformative Shifts in the DNA Sequencing Landscape

The DNA sequencing landscape is being reshaped by faster library preparation, higher-throughput instruments, improved read accuracy, and expanding use of long-read and multi-omics approaches. Short-read sequencing remains central for many clinical and research workflows due to established protocols and broad bioinformatics support, while long-read sequencing is gaining relevance for structural variants, repeat expansions, haplotype phasing, and complex genomic regions that are difficult to resolve with shorter reads. Clinical laboratories are increasingly emphasizing automation, sample-to-answer workflows, quality management, and interoperability with electronic health records. Public health agencies are also integrating genomic surveillance into outbreak response, building on lessons from global pathogen monitoring. The most important industry shift is the movement from episodic sequencing projects toward continuous genomic intelligence systems that link sample processing, variant interpretation, data security, and decision support.

Cumulative Impact of Artificial Intelligence on DNA Sequencing

Artificial intelligence is accelerating DNA sequencing by improving base calling, read alignment, variant prioritization, annotation, quality control, and clinical interpretation. Machine learning models are particularly valuable for detecting complex variant patterns, filtering sequencing artifacts, classifying variants of uncertain significance, and integrating genomic findings with phenotypic and clinical data. AI-enabled bioinformatics can reduce manual review burdens and support scalable analysis across oncology panels, whole-exome sequencing, whole-genome sequencing, pharmacogenomics, metagenomics, and single-cell datasets. However, the cumulative impact of AI depends on transparent model validation, bias assessment, explainability, secure data access, and compliance with medical device, laboratory, and privacy regulations. Industry leaders are increasingly adopting human-in-the-loop systems in which AI supports triage and interpretation while qualified professionals retain accountability for clinical reporting and patient safety.

Key Regional Insights for DNA Sequencing

North America remains highly advanced in clinical genomics, oncology testing, rare disease sequencing, newborn screening research, and population health initiatives, supported by mature laboratory networks, strong regulatory oversight, and deep bioinformatics capability. Europe demonstrates strong adoption through coordinated genomic strategies, privacy-focused data frameworks, cross-border research programs, and growing integration of sequencing into national healthcare pathways. Asia-Pacific is becoming a major growth engine for DNA sequencing adoption due to expanding genomic medicine programs, rising clinical research activity, broader infectious disease surveillance, and increasing investment in biotechnology infrastructure across China, Japan, India, South Korea, Australia, and ASEAN economies. Latin America is progressing through academic medical centers, public health laboratories, and regional reference networks, with Brazil and Mexico playing important roles in infectious disease genomics and hereditary disease research despite persistent gaps in funding and access. Africa's sequencing ecosystem is strengthening through pathogen genomics, antimicrobial resistance surveillance, biodiversity research, and capacity-building programs, with sustained emphasis needed on local laboratory infrastructure, data sovereignty, and skilled bioinformatics talent. The Middle East is advancing through national genome initiatives, precision medicine investments, and hospital-based genomic services, particularly where healthcare modernization and population health programs are policy priorities.

Key Group Insights for DNA Sequencing

NATO member countries contribute to DNA sequencing through biosecurity, infectious disease monitoring, defense-related health research, and resilient genomic surveillance systems that support preparedness against biological threats. G7 countries remain central to DNA sequencing innovation, regulatory science, clinical adoption, and advanced bioinformatics, with strong roles in oncology, pharmacogenomics, rare disease diagnostics, and pathogen surveillance. The European Union is distinguished by coordinated genomics initiatives, strong ethical and privacy governance, and emphasis on interoperable genomic data use across healthcare and research, creating a structured environment for clinical sequencing expansion. BRICS economies are highly influential because they combine large populations, substantial disease diversity, growing biotechnology capabilities, and increasing public health sequencing activity, although access, standardization, and workforce development vary widely. ASEAN countries are strengthening DNA sequencing capabilities through infectious disease surveillance, oncology research, agricultural genomics, and academic-clinical partnerships, while uneven laboratory infrastructure and reimbursement policies continue to shape adoption patterns across member states. The GCC is prioritizing genomic medicine through national health transformation agendas, population genomics, rare disease diagnosis, and precision oncology, supported by modern hospital systems and rising interest in data-driven healthcare.

Key Country Insights for DNA Sequencing

The United States leads in clinical DNA sequencing implementation across oncology, rare disease, reproductive health, pharmacogenomics, and public health genomics, supported by advanced laboratories, regulatory oversight, and extensive biomedical research networks. China has substantial sequencing capacity across population genomics, reproductive health, oncology, agriculture, and infectious disease surveillance, with growing emphasis on domestic innovation and data governance. Germany is advancing genomic diagnostics through strong clinical laboratories, translational research, and industrial biotechnology capabilities, while the United Kingdom has built one of the most structured national genomics environments, integrating sequencing into healthcare pathways, cancer diagnostics, rare disease programs, and population genomics. Canada emphasizes precision health, rare disease research, cancer genomics, and public health sequencing, with attention to equitable access across provinces and remote communities. Japan combines advanced clinical research, cancer genomics, aging-related studies, and high-quality laboratory standards, while India is rapidly strengthening its genomics ecosystem through population-scale research, rare disease initiatives, pathogen sequencing, agriculture, and cost-sensitive diagnostics. France is focusing on national genomic medicine implementation, oncology, rare disease diagnostics, and data governance. Mexico is expanding sequencing through infectious disease monitoring, hereditary cancer research, and academic medical collaborations, while Brazil has a prominent role in Latin American genomics through pathogen surveillance, biodiversity-related sequencing, and clinical research. South Korea is advancing precision medicine, oncology sequencing, rare disease diagnosis, and digital health integration through sophisticated hospital systems and national biotechnology priorities. Italy and Spain are expanding clinical sequencing in oncology, inherited disease, reproductive medicine, and academic hospital networks. Australia supports sequencing through national genomic medicine programs, public health genomics, Indigenous health considerations, and strong research infrastructure. Russia maintains sequencing activity across biomedical research, infectious disease monitoring, and agriculture, though integration into routine clinical care is shaped by infrastructure and policy conditions.

Actionable Recommendations for DNA Sequencing Leaders

Industry leaders should prioritize clinically validated sequencing workflows, scalable bioinformatics, and secure data architectures that support interoperability with laboratory information systems and electronic health records. Organizations expanding into clinical DNA sequencing should invest in accreditation-ready quality management, standardized variant classification, proficiency testing, and multidisciplinary genomic interpretation teams. To improve adoption, leaders should align sequencing services with clear use cases such as oncology therapy selection, rare disease diagnosis, infectious disease surveillance, pharmacogenomics, and reproductive health. AI should be deployed selectively for high-value functions such as quality control, variant prioritization, and report generation, with documented validation and human oversight. Partnerships with hospitals, public health agencies, academic centers, and payer stakeholders can improve evidence generation, clinical utility assessment, and reimbursement readiness. Executives should also strengthen cybersecurity, consent management, data localization compliance, and long-term genomic data stewardship to maintain trust in sequencing-enabled healthcare.

Research Methodology

This executive summary is developed using a structured secondary research approach based on verified public sources, including peer-reviewed scientific literature, clinical practice guidelines, regulatory agency publications, public health genomics resources, national genomics program documentation, standards-setting bodies, and healthcare policy references. The analysis emphasizes evidence-backed trends in sequencing technologies, clinical implementation, bioinformatics, artificial intelligence, regional adoption, and governance requirements. Information was assessed for relevance, recency, source credibility, and consistency across independent references. The methodology avoids speculative market sizing, market share analysis, and forecasting, focusing instead on observable industry developments, validated applications, policy direction, and operational implications for stakeholders in DNA sequencing.

Conclusion

DNA sequencing is moving from a specialized research capability to a core infrastructure for precision medicine, public health, and biological innovation. The most significant opportunities lie in clinically actionable genomics, AI-assisted interpretation, long-read sequencing, pathogen surveillance, population health programs, and secure integration of genomic data into healthcare systems. Adoption will be strongest where laboratories can demonstrate analytical validity, clinical utility, regulatory compliance, data protection, and sustainable reimbursement pathways. Regional and country-level progress shows that DNA sequencing is no longer concentrated in a single geography; it is becoming a global capability shaped by healthcare priorities, public health preparedness, and biotechnology investment. Organizations that combine robust sequencing workflows with trusted interpretation, ethical data governance, and clear clinical value will be best positioned to lead the next phase of genomic transformation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. DNA Sequencing Market, by Offerings

  • 7.1. Introduction
  • 7.2. Consumables & Reagents
    • 7.2.1. Enzymes & Buffers
    • 7.2.2. Primers & Probes
    • 7.2.3. Sequencing Kits
  • 7.3. Instruments & Platforms
    • 7.3.1. DNA Sequencers
    • 7.3.2. Library Preparation Systems
    • 7.3.3. PCR Machines
  • 7.4. Services
    • 7.4.1. Contract Sequencing
    • 7.4.2. Bioinformatics & Data Analysis Services
  • 7.5. Software
    • 7.5.1. Base Calling Software
    • 7.5.2. Clinical Interpretation Platforms
    • 7.5.3. Structural Variant Detection

8. DNA Sequencing Market, by Technology Type

  • 8.1. Introduction
  • 8.2. Next-Generation Sequencing (NGS)
    • 8.2.1. Sequencing by Synthesis
    • 8.2.2. Nanopore Sequencing
    • 8.2.3. Ion Semiconductor Sequencing
  • 8.3. Sanger Sequencing
  • 8.4. Third-Generation Sequencing (TGS)
  • 8.5. Epigenetic Sequencing
    • 8.5.1. Bisulfite Sequencing
    • 8.5.2. ChIP sequencing

9. DNA Sequencing Market, by Sample Type

  • 9.1. Introduction
  • 9.2. Human Samples
    • 9.2.1. Blood
    • 9.2.2. Saliva & Buccal Swab
    • 9.2.3. Urine
    • 9.2.4. Cell-Free DNA
    • 9.2.5. Tissue
    • 9.2.6. Plasma
  • 9.3. Animal Samples
  • 9.4. Plant Samples
    • 9.4.1. Leaf
    • 9.4.2. Root
    • 9.4.3. Seed
  • 9.5. Microbial Samples
    • 9.5.1. Bacteria
    • 9.5.2. Viruses
    • 9.5.3. Fungi
    • 9.5.4. Archaea

10. DNA Sequencing Market, by Application

  • 10.1. Introduction
  • 10.2. Clinical Diagnostics
    • 10.2.1. Oncology
    • 10.2.2. Infectious Disease Diagnosis
    • 10.2.3. Rare Disease & Genetic Disorder Testing
    • 10.2.4. Reproductive Health & Prenatal Testing
    • 10.2.5. Newborn Screening
  • 10.3. Research Applications
    • 10.3.1. Genomics & Transcriptomics
    • 10.3.2. Functional Genomics
    • 10.3.3. Epigenetics Research
  • 10.4. Drug Discovery & Development
    • 10.4.1. Biomarker Discovery
    • 10.4.2. Companion Diagnostics
    • 10.4.3. Target Identification & Validation
  • 10.5. Agrigenomics
    • 10.5.1. Plant Breeding & Trait Discovery
    • 10.5.2. Crop Pathogen Surveillance
  • 10.6. Forensics & Security
    • 10.6.1. Human Identification
    • 10.6.2. Criminal Investigation
    • 10.6.3. Disaster Victim Identification

11. DNA Sequencing Market, by End User

  • 11.1. Introduction
  • 11.2. Academic & Research Institutions
    • 11.2.1. Government Research Institutes
    • 11.2.2. University Labs
  • 11.3. Contract Research Organizations
  • 11.4. Hospitals & Diagnostic Laboratories
  • 11.5. Pharmaceutical & Biotechnology Companies

12. DNA Sequencing Market, by Region

  • 12.1. North America
  • 12.2. Europe
  • 12.3. Asia-Pacific
  • 12.4. Latin America
  • 12.5. Africa
  • 12.6. Middle East

13. DNA Sequencing Market, by Group

  • 13.1. NATO
  • 13.2. G7
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. ASEAN
  • 13.6. GCC

14. DNA Sequencing Market, by Country

  • 14.1. United States
  • 14.2. China
  • 14.3. Germany
  • 14.4. United Kingdom
  • 14.5. Canada
  • 14.6. Japan
  • 14.7. India
  • 14.8. France
  • 14.9. Mexico
  • 14.10. Brazil
  • 14.11. South Korea
  • 14.12. Italy
  • 14.13. Australia
  • 14.14. Russia
  • 14.15. Spain

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Illumina, Inc.
  • 16.2. Thermo Fisher Scientific Inc.
  • 16.3. BGI Genomics Co., Ltd.
  • 16.4. Oxford Nanopore Technologies PLC
  • 16.5. Pacific Biosciences of California, Inc.
  • 16.6. F. Hoffmann-La Roche Ltd.
  • 16.7. Novogene Co, Ltd.
  • 16.8. Laboratory Corporation of America Holdings
  • 16.9. Eurofins Scientific SE
  • 16.10. QIAGEN N.V.
  • 16.11. Azenta, Inc.
  • 16.12. Agilent Technologies, Inc.
  • 16.13. Twist Bioscience Corporation
  • 16.14. 10x Genomics, Inc.
  • 16.15. Abbott Laboratories
  • 16.16. AbbVie Inc.
  • 16.17. Becton, Dickinson and Company
  • 16.18. Bio-Rad Laboratories, Inc.
  • 16.19. BioChain Institute Inc.
  • 16.20. Charles River Laboratories International, Inc.
  • 16.21. Danaher Corporation
  • 16.22. Eppendorf SE
  • 16.23. GeneDx, LLC
  • 16.24. Genomics England
  • 16.25. Genscript Biotech Corporation
  • 16.26. Johnson & Johnson Services, Inc.
  • 16.27. Macrogen Inc.
  • 16.28. Merck KGaA
  • 16.29. Myriad Genetics, Inc.
  • 16.30. Novartis AG
  • 16.31. Partek Inc.
  • 16.32. PerkinElmer, Inc.
  • 16.33. Sartorius AG
  • 16.34. Shimadzu Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL DNA SEQUENCING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL DNA SEQUENCING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL DNA SEQUENCING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL DNA SEQUENCING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL DNA SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DNA SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL DNA SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL DNA SEQUENCING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL DNA SEQUENCING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL DNA SEQUENCING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL DNA SEQUENCING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL DNA SEQUENCING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL DNA SEQUENCING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL DNA SEQUENCING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL DNA SEQUENCING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL DNA SEQUENCING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL DNA SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CONSUMABLES & REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONSUMABLES & REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CONSUMABLES & REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENZYMES & BUFFERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENZYMES & BUFFERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENZYMES & BUFFERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PRIMERS & PROBES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PRIMERS & PROBES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PRIMERS & PROBES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SEQUENCING KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SEQUENCING KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SEQUENCING KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INSTRUMENTS & PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INSTRUMENTS & PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INSTRUMENTS & PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DNA SEQUENCERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DNA SEQUENCERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DNA SEQUENCERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LIBRARY PREPARATION SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LIBRARY PREPARATION SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LIBRARY PREPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PCR MACHINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PCR MACHINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PCR MACHINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CONTRACT SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CONTRACT SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CONTRACT SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BASE CALLING SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BASE CALLING SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BASE CALLING SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CLINICAL INTERPRETATION PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CLINICAL INTERPRETATION PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CLINICAL INTERPRETATION PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL STRUCTURAL VARIANT DETECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL STRUCTURAL VARIANT DETECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL STRUCTURAL VARIANT DETECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEXT-GENERATION SEQUENCING (NGS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEXT-GENERATION SEQUENCING (NGS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEXT-GENERATION SEQUENCING (NGS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SEQUENCING BY SYNTHESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SEQUENCING BY SYNTHESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SEQUENCING BY SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NANOPORE SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NANOPORE SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NANOPORE SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ION SEMICONDUCTOR SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ION SEMICONDUCTOR SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ION SEMICONDUCTOR SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SANGER SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SANGER SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SANGER SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL THIRD-GENERATION SEQUENCING (TGS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL THIRD-GENERATION SEQUENCING (TGS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL THIRD-GENERATION SEQUENCING (TGS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL EPIGENETIC SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL EPIGENETIC SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL EPIGENETIC SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BISULFITE SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BISULFITE SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BISULFITE SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CHIP SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CHIP SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CHIP SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DNA SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HUMAN SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HUMAN SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HUMAN SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SALIVA & BUCCAL SWAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SALIVA & BUCCAL SWAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL SALIVA & BUCCAL SWAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL URINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL URINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CELL-FREE DNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELL-FREE DNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CELL-FREE DNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL TISSUE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL TISSUE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL TISSUE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PLASMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PLASMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PLASMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANIMAL SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANIMAL SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANIMAL SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PLANT SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PLANT SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PLANT SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL LEAF MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL LEAF MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL LEAF MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ROOT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ROOT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ROOT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL SEED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL SEED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL SEED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL MICROBIAL SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL MICROBIAL SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL MICROBIAL SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BACTERIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BACTERIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BACTERIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL VIRUSES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL VIRUSES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL VIRUSES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL FUNGI MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL FUNGI MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL FUNGI MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ARCHAEA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ARCHAEA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ARCHAEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CLINICAL DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CLINICAL DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CLINICAL DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL INFECTIOUS DISEASE DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL INFECTIOUS DISEASE DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL INFECTIOUS DISEASE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL RARE DISEASE & GENETIC DISORDER TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL RARE DISEASE & GENETIC DISORDER TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL RARE DISEASE & GENETIC DISORDER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL REPRODUCTIVE HEALTH & PRENATAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL REPRODUCTIVE HEALTH & PRENATAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL REPRODUCTIVE HEALTH & PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEWBORN SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL NEWBORN SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL RESEARCH APPLICATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL RESEARCH APPLICATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL RESEARCH APPLICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL GENOMICS & TRANSCRIPTOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL GENOMICS & TRANSCRIPTOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL GENOMICS & TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL EPIGENETICS RESEARCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL EPIGENETICS RESEARCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL EPIGENETICS RESEARCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL TARGET IDENTIFICATION & VALIDATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL TARGET IDENTIFICATION & VALIDATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL TARGET IDENTIFICATION & VALIDATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL AGRIGENOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL AGRIGENOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL AGRIGENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL PLANT BREEDING & TRAIT DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL PLANT BREEDING & TRAIT DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL PLANT BREEDING & TRAIT DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL CROP PATHOGEN SURVEILLANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL CROP PATHOGEN SURVEILLANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL CROP PATHOGEN SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL FORENSICS & SECURITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL FORENSICS & SECURITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL FORENSICS & SECURITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL HUMAN IDENTIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL HUMAN IDENTIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL HUMAN IDENTIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL CRIMINAL INVESTIGATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL CRIMINAL INVESTIGATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL CRIMINAL INVESTIGATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL DISASTER VICTIM IDENTIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL DISASTER VICTIM IDENTIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL DISASTER VICTIM IDENTIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL DNA SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL GOVERNMENT RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL GOVERNMENT RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL GOVERNMENT RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL UNIVERSITY LABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL UNIVERSITY LABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL UNIVERSITY LABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL HOSPITALS & DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL HOSPITALS & DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL HOSPITALS & DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL DNA SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 214. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 216. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 218. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY EPIGENETIC SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 222. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY HUMAN SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 224. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY PLANT SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY MICROBIAL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 226. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 228. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 230. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY AGRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY FORENSICS & SECURITY, 2018-2032 (USD MILLION)
  • TABLE 232. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE DNA SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE DNA SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE DNA SEQUENCING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE DNA SEQUENCING MARKET SIZE, BY EPIGENETIC SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE DNA SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE DNA SEQUENCING MARKET SIZE, BY HUMAN SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE DNA SEQUENCING MARKET SIZE, BY PLANT SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE DNA SEQUENCING MARKET SIZE, BY MICROBIAL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE DNA SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE DNA SEQUENCING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE DNA SEQUENCING MARKET SIZE, BY AGRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE DNA SEQUENCING MARKET SIZE, BY FORENSICS & SECURITY, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE DNA SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC DNA SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC DNA SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC DNA SEQUENCING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC DNA SEQUENCING MARKET SIZE, BY EPIGENETIC SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC DNA SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC DNA SEQUENCING MARKET SIZE, BY HUMAN SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC DNA SEQUENCING MARKET SIZE, BY PLANT SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC DNA SEQUENCING MARKET SIZE, BY MICROBIAL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC DNA SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC DNA SEQUENCING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC DNA SEQUENCING MARKET SIZE, BY AGRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC DNA SEQUENCING MARKET SIZE, BY FORENSICS & SECURITY, 2018-2032 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC DNA SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 276. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 278. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 280. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 282. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 284. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY EPIGENETIC SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY HUMAN SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY PLANT SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 288. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY MICROBIAL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 290. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 292. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY AGRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 294. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY FORENSICS & SECURITY, 2018-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 297. AFRICA DNA SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 298. AFRICA DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 299. AFRICA DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 300. AFRICA DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 301. AFRICA DNA SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 302. AFRICA DNA SEQUENCING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 303. AFRICA DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. AFRICA DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 305. AFRICA DNA SEQUENCING MARKET SIZE, BY EPIGENETIC SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 306. AFRICA DNA SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. AFRICA DNA SEQUENCING MARKET SIZE, BY HUMAN SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 308. AFRICA DNA SEQUENCING MARKET SIZE, BY PLANT SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 309. AFRICA DNA SEQUENCING MARKET SIZE, BY MICROBIAL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 310. AFRICA DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 311. AFRICA DNA SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 312. AFRICA DNA SEQUENCING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 313. AFRICA DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 314. AFRICA DNA SEQUENCING MARKET SIZE, BY AGRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 315. AFRICA DNA SEQUENCING MARKET SIZE, BY FORENSICS & SECURITY, 2018-2032 (USD MILLION)
  • TABLE 316. AFRICA DNA SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 317. AFRICA DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 318. MIDDLE EAST DNA SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 320. MIDDLE EAST DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 321. MIDDLE EAST DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 322. MIDDLE EAST DNA SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 323. MIDDLE EAST DNA SEQUENCING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 324. MIDDLE EAST DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. MIDDLE EAST DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 326. MIDDLE EAST DNA SEQUENCING MARKET SIZE, BY EPIGENETIC SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 327. MIDDLE EAST DNA SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 328. MIDDLE EAST DNA SEQUENCING MARKET SIZE, BY HUMAN SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 329. MIDDLE EAST DNA SEQUENCING MARKET SIZE, BY PLANT SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 330. MIDDLE EAST DNA SEQUENCING MARKET SIZE, BY MICROBIAL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 331. MIDDLE EAST DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 332. MIDDLE EAST DNA SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 333. MIDDLE EAST DNA SEQUENCING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 334. MIDDLE EAST DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 335. MIDDLE EAST DNA SEQUENCING MARKET SIZE, BY AGRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 336. MIDDLE EAST DNA SEQUENCING MARKET SIZE, BY FORENSICS & SECURITY, 2018-2032 (USD MILLION)
  • TABLE 337. MIDDLE EAST DNA SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 338. MIDDLE EAST DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 339. GLOBAL DNA SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 340. NATO DNA SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 341. NATO DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 342. NATO DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 343. NATO DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 344. NATO DNA SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 345. NATO DNA SEQUENCING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 346. NATO DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 347. NATO DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 348. NATO DNA SEQUENCING MARKET SIZE, BY EPIGENETIC SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 349. NATO DNA SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 350. NATO DNA SEQUENCING MARKET SIZE, BY HUMAN SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 351. NATO DNA SEQUENCING MARKET SIZE, BY PLANT SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 352. NATO DNA SEQUENCING MARKET SIZE, BY MICROBIAL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 353. NATO DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 354. NATO DNA SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 355. NATO DNA SEQUENCING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 356. NATO DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 357. NATO DNA SEQUENCING MARKET SIZE, BY AGRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 358. NATO DNA SEQUENCING MARKET SIZE, BY FORENSICS & SECURITY, 2018-2032 (USD MILLION)
  • TABLE 359. NATO DNA SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 360. NATO DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 361. G7 DNA SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 362. G7 DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 363. G7 DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 364. G7 DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 365. G7 DNA SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 366. G7 DNA SEQUENCING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD